How Praluent Works: Mechanism, Benefits, and What to Expect

How Praluent Works

Praluent (alirocumab) lowers LDL cholesterol by binding to and inhibiting a protein called PCSK9. When PCSK9 is blocked, the liver has more LDL receptors available to pull LDL out of the bloodstream, which directly reduces circulating LDL levels. This makes it particularly useful for people with hereditary high cholesterol or those who cannot get their levels under control with statins alone.

The PCSK9 Pathway

PCSK9 is a natural protein that tags LDL receptors on liver cells for destruction. Fewer receptors mean less LDL is cleared. Praluent, a monoclonal antibody, binds to PCSK9 and prevents it from doing this, effectively increasing the number of active receptors. The result is a significant and sustained drop in LDL cholesterol.

Who Typically Uses Praluent

• People with familial hypercholesterolemia
• Patients with established cardiovascular disease who need additional LDL lowering
• Adults with high LDL that does not respond adequately to statin therapy
• Individuals who cannot tolerate statins

How It Is Taken and What Results Look Like

Praluent is injected under the skin, usually every two or four weeks, depending on the prescribed dose. LDL reductions of 50% to 60% are common when used alongside a statin. Many patients see measurable changes within four to eight weeks of starting treatment.

Side Effects and Practical Considerations

Injection-site reactions such as redness or swelling are the most common side effects. Because Praluent is a biologic, it requires ongoing use to maintain its effect; stopping the drug typically leads to LDL levels rising again. It is also expensive without insurance coverage, so prior authorization is often required.

Praluent vs. Other PCSK9 Inhibitors